Home | Sitemap | Search | ContactA- A A+
    Public Member Support us  

IBCSG 18-98 / BIG 1-98 

Adjuvant therapy for postmenopausal patients with operable breast cancer who have estrogen receptor or progesteron receptor positive tumor.

Tamoxifen vs. letrozole vs. tamoxifen followed by letrozole vs. letrozole followed by tamoxifen


Design Trial 18-98

Results & Publications



Study Chair
Prof. Beat Thürlimann - St. Gallen, Switzerland

Anita Giobbie-Hurder
Dr. Zhuoxin Sun

Lead Trial Coordinator
Holly Shaw

Data Managers
Susan Fischer

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg18_BIG1-98@fstrf.org

Date of Activation
March, 1998

Date of Closure
Core Protocol: May 13, 2003
GS/SLP Substudy: February 7, 2003
BMD Substudy: February 7, 2003
New Bone Substudy: January 31, 2007
Fingernail Pilot Substudy: July 31, 2007
Cognitive Function Substudy: May 20, 2008

Final Accrual
Core Protocol: 8028 patients
GS/SLP Substudy: 65 patients
BMD Substudy: 39 patients
New Bone Substudy: 458 patients
Fingernail Pilot Substudy: 16 patients
Cognitive Function Substudy: 135 patients

Results Publications Results & Publications
Other Pathology


New publications are available 

IBCSG is proud to contribute nine abstracts to the upcoming San Antonio Breast Cancer Symposium

Clinical Trials

All News